Attention IASLC Voting Members!!

Check your email for "Your Vote Matters: Cast Your Ballot on IASLC Bylaws Today" OR cast your ballot here: https://app.propfuel.com/checkin/embed/0134a829-044f-4013-9a86-9673a398e121

Complete Response to Pembrolizumab as Monotherapy in a Patient with Baseline Stage IV NSCLC with Very High PD-L1 Expression

Pecci ACR graphic

Download (1.62 MB)

General

Complete Response to Pembrolizumab as Monotherapy in a Patient with Baseline Stage IV NSCLC with Very High PD-L1 Expression

Federica Pecci, MD
Italy